Η ΕΠΙΤΕΥΞΗ ΤΗΣ uMRD* ΑΠΟΤΕΛΕΙ ΕΝΑ ΣΗΜΑΝΤΙΚΟ ΣΤΟΧΟ ΚΑΙ
ΕΝΔΕΧΕΤΑΙ ΝΑ ΣΥΣΧΕΤΙΖΕΤΑΙ ΜΕ ΒΕΛΤΙΩΜΕΝΗ ΠΡΟΓΝΩΣΗ4,5,6
Achieving a deep response* is important and may be associated with improved outcomes1,2
*uMRD = μη ανιχνεύσιμη ελάχιστη υπολειμμματική νόσος
I want to find out
more
about VENCLYXTO
I want to receive more information
about VENCLYXTO
Παραπομπές: 4. Mato AR, Roeker LE, Jacobs R, et al. Assessment of efficacy of therapies following venetoclax discontinuation in CLL reveals BTI inhibition as an effective strategy. Clin Cancer Res. 2020;26(14):3589-3596. 5. Kater AP, Owen C, Moreno C, et al. Fixed-duration ibrutinib-venetoclax in patients with chronic lymphocytic leukemia and comorbidities. NEJM Evid. 2022;1(7):1-13. 6. Niemann CU, Munir T, Moreno C, et al. Residual disease kinetics among patients with high-risk factors treated with first-line fixed-duration ibrutinib plus venetoclax versus chlorambucil plus obinutuzumab (Clb+O) the GLOW study. Poster presented at the American Society of Hematology Meeting 2022.